Bridging Anticoagulation: The BRIDGE Study on Atrial Fibrillation and Warfarin Therapy
March 2012
in “
Circulation
”
Studysummary This article discusses bridging anticoagulation for patients interrupting warfarin for surgery and highlights the need for the BRIDGE randomized trial to address current uncertainties about its effectiveness and safety.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document discussed bridging anticoagulation, which involves using a short-acting blood thinner to reduce blood clot risks when warfarin therapy is paused for surgery, but this may increase bleeding risks post-surgery. It introduced the BRIDGE study, a randomized trial aiming to assess the necessity of bridging anticoagulation in over 3600 patients with atrial fibrillation stopping warfarin for elective procedures, across the United States, Canada, and Brazil. The study was designed to address the lack of high-quality clinical data on who should receive bridging anticoagulation, highlighting the global impact of its potential findings.
